Last C$2.58 CAD
Change Today -0.09 / -3.37%
Volume 2.9K
I On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ CM
Frankfurt
As of 3:44 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

intellipharmaceutics interna (I) Snapshot

Open
C$2.68
Previous Close
C$2.67
Day High
C$2.68
Day Low
C$2.58
52 Week High
03/21/14 - C$5.77
52 Week Low
08/27/14 - C$2.14
Market Cap
60.5M
Average Volume 10 Days
4.8K
EPS TTM
C$-0.42
Shares Outstanding
23.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTELLIPHARMACEUTICS INTERNA (I)

Related News

No related news articles were found.

intellipharmaceutics interna (I) Related Businessweek News

No Related Businessweek News Found

intellipharmaceutics interna (I) Details

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled and targeted release oral solid dosage drugs in Canada. The company has a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, such as neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. Its products under FDA review include Focalin XR, an extended release capsule for hyperactivity disorders; Effexor XR, an extended release capsule for depression; Protonix, a tablet for gastroesophageal reflux diseases; Glucophage XR, a tablet for managing type 2 diabetes; Seroquel XR, a tablet for the treatment of schizophrenia, bipolar disorders, and depressive disorders; Lamictal XR, a tablet for anti-convulsant for epilepsy; and Keppra XR, a tablet for the treatment of partial onset seizures for epilepsy, as well as Pristiq, a tablet for depression. The company is also developing Coreg CR, a capsule, which is in late-stage development for heart failure and hypertension; OxyContin, a controlled release capsule that is in phase I clinical trial for pain; and Lyrica, a capsule, which is in phase I clinical trial for neuropathic pain. Its non-generic products under development include Rexista, an oral formulation for pain relief; and Regabati XR, a pregabalin extended release capsule that has completed an initial phase I clinical trial for neuropathic pain. The company has a license and commercialization agreement with Par Pharmaceutical, Inc. for the development and commercialization of generic Focalin XR. Intellipharmaceutics International Inc. is headquartered in Toronto, Canada.

38 Employees
Last Reported Date: 02/18/14

intellipharmaceutics interna (I) Top Compensated Officers

Co-Founder, Chairman, Chairman of Scientific ...
Total Annual Compensation: $509.7K
President, Chief Operating Officer, Principal...
Total Annual Compensation: $509.7K
Vice President of Legal Affairs & Licensing, ...
Total Annual Compensation: $141.6K
Compensation as of Fiscal Year 2013.

intellipharmaceutics interna (I) Key Developments

IntelliPharmaCeutics International Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015

IntelliPharmaCeutics International Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 . Venue: Westin St. Francis Hotel, San Francisco, California, United States.

IntelliPharmaCeutics International Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

IntelliPharmaCeutics International Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Intellipharmaceutics International Inc. Announces Appointment of Domenic Della Penna as New Chief Financial Officer, Effective November 24, 2014

Intellipharmaceutics International Inc. announced that it has appointed Domenic Della Penna as its new Chief Financial Officer, effective November 24, 2014. Mr. Della Penna brings considerable expertise and industry experience to the company. He had previously served as CFO of Teva Canada Limited since December 2010, and he had also simultaneously served as Interim CFO of Teva North America Generics in the United States since December 2013. His responsibilities and accomplishments in those roles included enhancements to strategic planning processes and financial systems, integration of assets acquired in the purchase of ratiopharm Canada by Teva, business development, and the negotiation of in-licensing opportunities, mergers and acquisitions. Prior to his time at Teva, Mr. Della Penna was the CFO of Timothy's Coffees of the World, and Vice President of Finance of Diageo Canada Inc.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
I:CN C$2.58 CAD -0.09

I Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,743 GBp -18.50
Durect Corp $0.94 USD -0.01
Lupin Ltd 1,585 INR +30.75
Torrent Pharmaceuticals Ltd 1,100 INR -38.70
View Industry Companies
 

Industry Analysis

I

Industry Average

Valuation I Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.4x
Price/Book 8.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTELLIPHARMACEUTICS INTERNA, please visit www.intellipharmaceutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.